A 4-YEAR EXPERIENCE WITH ANTHRACYCLINE, CYTOSINE-ARABINOSIDE, VINCRISTINE AND PREDNISONE COMBINATION CHEMOTHERAPY IN 325 ADULTS WITH ACUTE-LEUKEMIA
A 4-YEAR EXPERIENCE WITH ANTHRACYCLINE, CYTOSINE-ARABINOSIDE, VINCRISTINE AND PREDNISONE COMBINATION CHEMOTHERAPY IN 325 ADULTS WITH ACUTE-LEUKEMIA
复制标题
DOI：
10.1002/1097-0142(19810615)47:12
复制
发表时间：
1981-01-01
期刊：
影响因子：
6.2
通讯作者：
FREIREICH, EJ
中科院分区：
文献类型：
--
作者：
KEATING, MJ;SMITH, TL;FREIREICH, EJ
在325例连续未选择的急性白血病成人患者中，蒽环类药物、阿霉素或鲁比酮、阿糖胞嘧啶、长春新碱和强的松联合化疗导致62%的完全缓解率。急性髓性白血病（AML）占58%，急性未分化白血病（AUL）占70%，急性淋巴细胞白血病（ALL）占77%。中位生存期为43周。在所有患者中，预计有10%的患者存活并在5年内处于缓解期。整个组的中位缓解持续时间为51周，AML的持续时间（60周）明显超过all（30周）和AUL（21周）。中枢神经系统受累在AML中不常见（4%），但在AUL（37%）和ALL（32%）患者中更为常见。五分之一的急性髓性白血病完全缓解者预计在化疗结束5年后首次缓解。年龄、性别、形态、细胞遗传学模式、发病时的体温和既往血液学异常记录是影响疗效和生存率的重要变量。
Combination chemotherapy with an anthracycline, adriamycin or rubidazone, cytosine arabinoside, vincristine and prednisone resulted in a complete remission rate of 62% in 325 consecutive unselected adults with acute leukemia. The results by morphologic categories were 58% for acute myelogenous leukemia (AML), 70% for acute undifferentiated leukemia (AUL) and 77% for acute lymphoblastic leukemia (ALL). The median survival was 43 wk. Of all patients, 10% are projected to be alive and in remission at 5 yr. The median remission duration for the whole group was 51 wk, durations being significantly longer for AML (60 wk) than ALL (30 wk) and AUL (21 wk). CNS involvement was uncommon in AML (4%) but much more common in patients with AUL (37%) and ALL (32%). One in 5 complete responders with AML is projected to be in their 1st remission at 5 yr off all chemotherapy. Age, sex, morphology, cytogenetic pattern, temperature at presentation and presence of a documented preceding hematologic abnormality are significant variables for response and survival.